미국의 갱년기장애 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 지역별, 부문별 예측(2025-2033년)

U.S. Menopause Market Size & Trends:

The U.S. menopause market size was estimated at USD 5.56 billion in 2024 and is projected to reach USD 8.58 billion by 2033, growing at a CAGR of 5.0% from 2025 to 2033. The increasing number of women who are reaching menopause age and the rise in awareness and education and its related symptoms are resulting in a growing demand for related products, services, and treatments. According to the report published by the National Library of Medicine in 2023, approximately 1.3 million women experience menopause each year, typically between the age group of 45 to 55 in the U.S. Moreover, the increasing preference for natural and organic menopause remedies and the availability of innovative products and technologies in the market, such as hormone-free therapies and telemedicine services, are also contributing to the growth of the market in the U.S.

In addition, as per the Society for Women's health Research, as the millennial population is aging, the country has around 6,000 women are expected to enter menopause each day in the U.S. A survey conducted by AARP, a U.S.-based nonprofit organization, in January 2024, revealed that approximately 90% of women aged 35 and older experience menopausal symptoms that impact their daily lives and work activities. According to the World Health Organization (WHO), menopause typically begins between the ages of 45 to 56 years. Wherein there is a small proportion of women, approximately 5%, who experience it early, naturally which occurs between the ages of 40 and 45 years old. Furthermore, there is a rare condition known as primary ovarian insufficiency, in which only 1% of women undergo a complete stop of menstruation before the age of 40 due to permanent ovarian failure. Research from the National Library of Medicine indicates that women from certain ethnic backgrounds experience premature and early menopause more frequently than their counterparts from different communities. The incidence of premature menopause is 1.4% for Black and Hispanic women, while it is only 1% for White women.

U.S. Menopause Market Report Segmentation

This report forecasts revenue growth, country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033 for this study, Grand View Research has segmented the U.S. menopause market report based on type, country.

• Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Hormonal
• Non-Hormonal
• Dietary Supplements
• Country Outlook (Revenue, USD Billion, 2021 - 2033)
• Southeast
• West
• Midwest
• Southwest
• Northeast

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources & Third-Party Perspectives
  • 1.3.4. Primary Research
  • 1.3.5. Details of Primary Research
• 1.4. Information Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Data Visualization
  • 1.5.1. Commodity Flow Analysis
• 1.6. Data Validation & Publishing
• 1.7. List of Secondary Sources
• 1.8. Research Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segmental Snapshot
• 2.3. Competitive Insights Snapshot

Chapter 3. Market Variables, Trends, and Scope

• 3.1. Market Lineage
  • 3.1.1. Parent Market Analysis
  • 3.1.2. Ancillary Market Analysis
• 3.2. U.S. Menopause Market- Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Covid-19 Impact Analysis
• 3.4. Regulatory & Reimbursement Scenario
• 3.5. Business Environmental Tools Analysis: U.S. Menopause Market
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTLE Analysis

Chapter 4. U.S. Menopause Market: Type Estimates & Trend Analysis

• 4.1. U.S. Menopause Market, By Type: Key Takeaways
• 4.2. U.S. Menopause Market: Type Movement & Market Share Analysis, 2024 & 2033
• 4.3. Hormonal
  • 4.3.1. Hormonal Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.4. Non-Hormonal
  • 4.4.1. Non-Hormonal Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.5. Dietary Supplements
  • 4.5.1. Dietary Supplements Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. U.S. Menopause Market: Country Estimates & Trend Analysis

• 5.1. U.S. Menopause Market, By Regional: Key Takeaways
• 5.2. U.S. Menopause Market: Regional Movement & Market Share Analysis, 2024 & 2033
• 5.3. West
  • 5.3.1. West Menopause Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.4. Southeast
  • 5.4.1. Southeast Menopause Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.5. Southwest
  • 5.5.1. Southwest Menopause Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.6. Midwest
  • 5.6.1. Midwest Menopause Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.7. Northeast
  • 5.7.1. Northeast Menopause Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Competitive Landscape

• 6.1. Company Categorization
• 6.2. Company Market Position Analysis
• 6.3. Strategy Mapping
• 6.4. Company Profiles
  • 6.4.1. Pfizer Inc.
    • 6.4.1.1. Overview
    • 6.4.1.2. Financial Performance
    • 6.4.1.3. Product Benchmarking
    • 6.4.1.4. Strategic Initiatives
  • 6.4.2. Novo Nordisk A/S
    • 6.4.2.1. Overview
    • 6.4.2.2. Financial Performance
    • 6.4.2.3. Product Benchmarking
    • 6.4.2.4. Strategic Initiatives
  • 6.4.3. TherapeuticsMD
    • 6.4.3.1. Overview
    • 6.4.3.2. Financial Performance
    • 6.4.3.3. Product Benchmarking
    • 6.4.3.4. Strategic Initiatives
  • 6.4.4. Bayer AG
    • 6.4.4.1. Overview
    • 6.4.4.2. Financial Performance
    • 6.4.4.3. Product Benchmarking
    • 6.4.4.4. Strategic Initiatives
  • 6.4.5. AbbVie, Inc.
    • 6.4.5.1. Overview
    • 6.4.5.2. Financial Performance
    • 6.4.5.3. Product Benchmarking
    • 6.4.5.4. Strategic Initiatives
  • 6.4.6. Pure Encapsulations, LLC.
    • 6.4.6.1. Overview
    • 6.4.6.2. Financial Performance
    • 6.4.6.3. Product Benchmarking
    • 6.4.6.4. Strategic Initiatives
  • 6.4.7. PADAGIS LLC
    • 6.4.7.1. Overview
    • 6.4.7.2. Financial Performance
    • 6.4.7.3. Product Benchmarking
    • 6.4.7.4. Strategic Initiatives